Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia.

Article Details

Citation

Denes L, Szilagyi G, Gal A, Nagy Z

Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia.

Brain Res Bull. 2006 Jul 31;70(3):260-2. Epub 2006 Mar 31.

PubMed ID
16861112 [ View in PubMed
]
Abstract

Talampanel (IVAX) is a non-competitive AMPA-antagonist has a remarkable neuroprotection in different rodent stroke models. The focal cerebral ischemia in mice was induced by transient (60 min.) MCA occlusion and 48 h reperfusion and treated with talampanel (6 x 2 mg/kg, i.p.). The apoptotic and necrotic cells were analyzed by double immune histochemical staining on confocal laser microscope. The infarct size is decreased significantly by talampanel treatment (from 57.1+/-7.2mm(2) to 18.9+/-2.6 mm(2), p< 0.001). The number of TUNEL-positive cells localized mostly in the border zone of ischemic lesions is significantly decreased after talampanel treatment (from 962+/-13.0 to 604+/-6.9, p < 0.01). A strong, significant reduction of caspase-3 active cells was visualized. Talampanel as a neuroprotective drug candidate has a significant effect in mice transient MCA occlusion model.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
TalampanelGlutamate receptor 1ProteinHumans
Unknown
Not AvailableDetails
TalampanelGlutamate receptor 2ProteinHumans
Unknown
Not AvailableDetails
TalampanelGlutamate receptor 3ProteinHumans
Unknown
Not AvailableDetails
TalampanelGlutamate receptor 4ProteinHumans
Unknown
Not AvailableDetails